Validation of ABO Gene Expression in Normal Tissues and Acute Myeloid Leukaemia Using In-Silico Approaches

Background:-This study investigates the association between the ABO blood group genes and acute myeloid leukaemia (AML), a cancer characterized by rapid growth of abnormal white blood cells. Prior research indicates a potential link between blood group antigens and various cancers, including leukaemia. Our objective is to assess and validate changes in ABO gene expression in AML tissues compared to normal tissues, clarifying the extent of its association with AML pathogenesis and progression. Methods:-In-silico analysis using platforms like GeneCards, HPA, ARChS4, BioGPS, and GEPIA2 was conducted to gather detailed data on ABO gene localization and its expression at RNA, mRNA, and protein levels in normal. And AML patients, aiding in understanding gene functionality. Results:-The ABO gene was expressed in almost all subcellular components and throughout normal body tissues, including the myeloid tissues. A statistically significant association was found between the ABO gene expression and AML conditions in which the expression of the ABO gene is significantly suppressed in AML. There was worse survival for the AML patient with higher ABO expression without significant statistical evidence. Conclusion:-The results reveal a reverse association between ABO gene expression and AML, highlighting the need for further research to elucidate ABO's role in AML progression.